Phagocytosis of Blood Cells by Splenic Macrophages in Thrombotic Thrombocytopenic Purpura

1975 ◽  
Vol 82 (6) ◽  
pp. 799 ◽  
Author(s):  
A. KADRI
2008 ◽  
Vol 16 (2) ◽  
pp. 224-227 ◽  
Author(s):  
Suresh G. Shelat

Described is a case of acute chest syndrome in a sickle-cell patient (hemoglobin SS) who also developed signs and symptoms of thrombotic thrombocytopenic purpura, including thrombocytopenia and hemolysis (anemia, elevated lactate dehydrogenase, presence of schistocytes, dark-colored plasma, and elevations in nucleated red blood cells). The ADAMTS13 activity level was normal. Discussed are the diagnosis and therapeutic management issues and the challenges of differentiating the vasoocclusive and hemolytic complications of sickling red blood cells from the thrombotic microangiopathy of thrombotic thrombocytopenic purpura.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 89-89
Author(s):  
Kai Wang ◽  
Khulan Batbayar ◽  
Karl Roberts ◽  
Emmanuel Olivier ◽  
Eric E. Bouhassira

Red Blood Cells (RBCs) have long been considered a potentially useful means of delivering drugs to the circulation because delivery through therapeutic RBCs as compared to direct injection in the plasma can lengthen the half-life of the therapeutic agent in the circulation, spatially restrict the drugs to the lumen of the cardio-vascular system, and shield the drug from the immune system. Despite some progress, loading the cells with therapeutically useful cargo remains technically challenging. We have recently developed PSC-RED, a chemically-defined scalable method to differentiate induced pluripotent stem cells (iPSCs) into unlimited numbers of enucleated cultured RBCs. This provides an ideal method to produce therapeutic RBCs since iPSCs can be genetically manipulated with powerful CRISPR-based technologies. ADAMTS13, whose deficiency is responsible for congenital and acquire Thrombotic Thrombocytopenic Purpura (TTP) is a good target as a therapeutic that could be delivered through drug-carrying RBCs because large amounts of plasma concentrate, or more recently recombinant proteins, are necessary to treat TTP. We report here we have produced engineered erythroid cells that contains globin-LCR driven ADAMTS13 fusion transgenes inserted at safe harbor AAVS1, and that these cells express a membrane bound version of an inhibitor-resistant version of ADAMTS13. We show using flow cytometry that the fusion protein is express at high levels, and using a FRET assay that detect cleavage of the von Willebrand cognate site, that the membrane bound ADAMTS13 is enzymatically active. Comparison of enzymatic activity with plasma concentrate suggests that about 50 billion engineered ADAMTS13-cRBCs would be sufficient to deliver an amount of ADAMTS13 equivalent to 2 liters of plasma concentrate. This suggests that a transfusion of about 10 mL of ADAMTS13-RBCs could be therapeutic for congenital and acquired TTP. The number of cRBCs necessary to treat even a few patients is very large. This has been considered a major obstacle to the development of treatment based on in vitro produced RBCs because of the volume of culture that is necessary to produce the cells. We also report that we have developed a culture method based on holo-fiber bioreactors that allows the production of cRBCs at a density of 5.108 cell/mL which is sufficient to produce enough cells to performed small clinical trials. Disclosures No relevant conflicts of interest to declare.


2013 ◽  
Vol 6 ◽  
pp. CCRep.S12122
Author(s):  
Wan Suriana Wan Ab Rahman ◽  
Wan Zaidah Abdullah ◽  
Rapiaah Mustaffa ◽  
Suhair Abbas Ahmed ◽  
Mohd Nazri Hassan ◽  
...  

Thrombotic thrombocytopenic purpura (TTP) is a medical emergency characterized by occlusive microangiopathy due to intravascular platelet aggregation. This event results in damage to the red blood cells (RBCs) known as microangiopathic hemolytic anemia (MAHA). Schistocytes are circulating fragments of damaged RBCs that have different morphological features including keratocytes, helmet cells, and spherocytes. It is critical to report even a small number of these abnormal RBCs in the peripheral blood and to be alert for the possible diagnosis of TTP, especially in unexplained anemia and thrombocytopenia. The application of pentad criteria in the diagnosis has been reviewed, and the challenges still remained on the hematologic evidence of this disorder. In the 3 cases discussed here, the red cell morphological diagnosis gave an impact on TTP diagnosis, but overdiagnosis might be encountered in obstetrical patients due to nonspecific diagnostic criteria.


Blood ◽  
1962 ◽  
Vol 19 (2) ◽  
pp. 181-199 ◽  
Author(s):  
JAMES B. MACWHINNEY ◽  
JAMES T. PACKER ◽  
GERALD MILLER ◽  
ROBERT M. GREENDYKE

Abstract (1) Two cases of thrombotic thrombocytopenic purpura (TTP) occurring in childhood are described. Case 1 is unique in that the patient survived for 12 years. (2) The clinical features of 19 reported cases of TTP in children are reviewed. (3) The presence of morphologic abnormalities of red blood cells and the regular occurrence of kidney involvement in this disorder is emphasized. In one patient (Case 2), histologic changes of the disease were limited to the kidney. (4) Certain hematologic and histologic features shared by TTP and eclampsia are described. (5) Unusual histologic lesions of renal vessels are described.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 12-13
Author(s):  
Frederick Van Moh ◽  
Debapria Das ◽  
Hourhan Houjeij ◽  
Adam J Fritz

Introduction: Thrombotic thrombocytopenic purpura (TTP) is a hematologic emergency where timely plasmapheresis reduces mortality. There are a few cases where benign etiologies mimic TTP and patients may receive unnecessary plasma exchange. Interdisciplinary decision-making is invaluable to avoid expenses and complications of more invasive treatments. Case Presentation: A 38-year-old male with self-reported history of asthma presented with generalized weakness and syncope. He endorses 2-week of bilateral leg pain with numbness, loss of taste, and nausea. Vital signs were remarkable for tachycardia in 110s and hypotension at 101/52. Labs showed hemoglobin 3.3, WBC 3.6, platelet 83, MCV 93.9, reticulocyte 1.1%, total bilirubin 1.4, haptoglobin <8, LDH 2652, negative Coombs test, and creatinine 1.2. Vitamin B12 level was >2000, however value was drawn near the time of administration of intramuscular vitamin B12. There was concern for TTP due to an intermediate PLASMIC score of 5. However, given that presentation was more consistent with vitamin B12 deficiency, plasmapheresis was deferred after a discussion with pathology. Peripheral blood smear showed anisocytosis, macrocytes, schistocytes, and hypersegmented neutrophils. ADAMTS13 activity returned 62%. Pernicious anemia was diagnosed with labs revealed homocysteine >50, methylmalonic acid 41.97, positive anti-parietal cell antibody, and positive intrinsic factor antibody. Hemoglobin stabilized at around 8 after transfusions. Lab showed haptoglobin 13 and LDH 1211 on discharged after daily vitamin B12 injections. Patient was discharged with weekly injections and last gastric biopsy reveal atrophic gastritis. Discussion: The decision to closely monitor our patient versus initiation of plasmapheresis was based on clinical symptoms of neuropathy and reduced taste consistent with vitamin B12 deficiency. Our patient's lab values and peripheral smear were also more reassuring of a nutritional deficiency. Severe vitamin B12 deficiency is thought to cause both intramedullary and extramedullary hemolysis. Intramedullary hemolysis caused by destruction of erythrocytes leading to ineffective erythropoiesis is more common. Conversely, the mechanism of extramedullary hemolysis is not well established. It is thought that the pro-oxidative qualities of homocysteine can promote thrombosis and endothelial dysfunction and subsequent microangiopathy. This phenomenon, commonly called pseudothrombotic microangiopathy, mimics TTP. Few laboratory values can help distinguish between TTP and an intramedullary process. First, reduced reticulocyte count suggests defective DNA synthesis and destruction of megaloblastic cells by bone marrow macrophages. A high MCV in the setting of low reticulocyte count is suggestive of vitamin B12 deficiency. Blood smear may also show multiple hypersegmented polymorphonuclear cells and macrocytosis in addition to schistocytes. Additionally, LDH tends to be more substantially elevated in intramedullary hemolytic processes like vitamin B12 deficiency. This is attributed to high LDH content of nucleated erythrocytes when compared to mature red blood cells. Immature erythrocytes contain less hemoglobin than mature red blood cells and bilirubin is relatively less elevated in vitamin B12 deficiency. Lastly, platelet counts tend to be higher in vitamin B12 deficiency than in TTP. Disclosures No relevant conflicts of interest to declare.


1981 ◽  
Vol 46 (02) ◽  
pp. 571-571 ◽  
Author(s):  
M Pini ◽  
C Manotti ◽  
R Quintavalla ◽  
A G Dettori

Sign in / Sign up

Export Citation Format

Share Document